Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
Экономическая оценка факторных исследований: анализ «затраты—полезность» в факторном исследовании AFORRD «Аторвастатин в факторной комбинации с омега-3 для снижения риска при сахарном диабете» с дизайном 2 × 2 × 2, изучающем аторвастатин, рыбий жир омега-3 и планирование действий
2020-08-18
SCID: 54.1/fgmn43sn
Discuss with AI
2 × 2 × 2 factorial trialatorvastatincost-effectiveness acceptability curvescost-utility analysisomega-3 fish oil
Figures from the paper
Abstract (AI)
OBJECTIVES: We applied principles for conducting economic evaluations of factorial trials to a trial-based economic evaluation of a cluster-randomized 2 × 2 × 2 factorial trial. We assessed the cost-effectiveness of atorvastatin, omega-3 fish oil, and an action-planning leaflet, alone and in combination, from a UK National Health Service perspective. METHODS: The Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes (AFORRD) Trial randomized 800 patients with type 2 diabetes to atorvastatin, omega-3, or their respective placebos and randomized general practices to receive a leaflet-based action-planning intervention designed to improve compliance or standard care. The trial was conducted at 59 UK general practices. Sixteen-week outcomes for each trial participant were extrapolated for 70 years using the United Kingdom Prospective Diabetes Study Outcomes Model v2.01. We analyzed the trial as a 2 × 2 factorial trial (ignoring interactions between action-planning leaflet and medication), as a 2 × 2 × 2 factorial trial (considering all interactions), and ignoring all interactions. RESULTS: We observed several qualitative interactions for costs and quality-adjusted life-years (QALYs) that changed treatment rankings. However, different approaches to analyzing the factorial design did not change the conclusions. There was a ≥99% chance that atorvastatin is cost-effective and omega-3 is not, at a £20 000/QALY threshold. CONCLUSIONS: Atorvastatin monotherapy was the most cost-effective combination of the 3 trial interventions at a £20 000/QALY threshold. Omega-3 fish oil was not cost-effective, while there was insufficient evidence to draw firm conclusions about action planning. Recently-developed methods for analyzing factorial trials and combining parameter and sampling uncertainty were extended to estimate cost-effectiveness acceptability curves within a 2x2x2 factorial design with model-based extrapolation.
Key Findings
1
A trial-based economic evaluation assessed atorvastatin, omega-3 fish oil, and an action-planning leaflet individually and in combination from the UK NHS perspective.
2
At a £20,000/QALY threshold, atorvastatin had at least a 99% probability of being cost-effective, whereas omega-3 fish oil was not cost-effective.
3
Atorvastatin monotherapy was the most cost-effective intervention combination; evidence was insufficient to determine whether action planning was cost-effective.
4
Qualitative interactions affected costs and QALYs and changed treatment rankings, but alternative analyses of the factorial design produced the same overall conclusions.
5
Sixteen-week trial outcomes from 800 patients across 59 UK general practices were extrapolated over 70 years using the UKPDS Outcomes Model v2.01.
6
The study extended factorial-trial methods for combining parameter and sampling uncertainty to estimate cost-effectiveness acceptability curves with model-based extrapolation.
Research Object
The 2 × 2 × 2 factorial trial interventions in patients with type 2 diabetes: atorvastatin, omega-3 fish oil, and a leaflet-based action-planning intervention
Research Subject
The cost-effectiveness of the interventions alone and in combination, including their effects on costs, quality-adjusted life-years, treatment rankings, and interactions
Publication Details
Publication Date
2020-08-18
Journal
Publisher
ISSN
Cited by
5
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
Statins for the primary prevention of cardiovascular disease2013
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease2018